{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:40:25Z","timestamp":1789371625317,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.vaccine.2011.02.037","type":"journal-article","created":{"date-parts":[[2011,2,27]],"date-time":"2011-02-27T14:05:40Z","timestamp":1298815540000},"page":"3222-3229","source":"Crossref","is-referenced-by-count":42,"title":["Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study"],"prefix":"10.1016","volume":"29","author":[{"given":"Janice M.","family":"Rusnak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Boudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise P.","family":"Clizbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.02.037_bib0005","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/path.1700340418","article-title":"Enzootic hepatitis or Rift Valley fever: an undescribed virus of sheep, cattle and man from East Africa","volume":"34","author":"Daubney","year":"1931","journal-title":"J Pathol Bacteriol"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0010","first-page":"261","article-title":"Rift Valley fever \u2013 East Africa, 1997\u20131998","volume":"47","author":"Centers for Disease Control","year":"1998","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0015","first-page":"73","article-title":"Rift Valley fever outbreak-Kenya, November 2006\u2013January 2007","volume":"56","author":"Centers for Disease Control","year":"2007","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0020","first-page":"982","article-title":"Update: outbreak of Rift Valley fever \u2013 Saudi Arabia, August\u2013November 2000","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1086\/345671","article-title":"Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans","volume":"36","author":"Al-Hazmi","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0030","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/378747","article-title":"Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics","volume":"37","author":"Madani","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0035","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4269\/ajtmh.2010.09-0669","article-title":"Severe Rift Valley fever may present with a characteristic clinical syndrome","volume":"82","author":"Kahlon","year":"2010","journal-title":"Am J Trop Med Hyg"},{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2011.02.037_bib0040","doi-asserted-by":"crossref","first-page":"S777","DOI":"10.1093\/clinids\/11.Supplement_4.S777","article-title":"Clinical aspects of African viral hemorrhagic fevers","volume":"2","author":"Gear","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0045","first-page":"803","article-title":"Rift Valley fever in humans in South Africa","volume":"58","author":"McIntosh","year":"1980","journal-title":"S Afr Med J"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0050","doi-asserted-by":"crossref","unstructured":"Britch SC, Linthicum KJ, the Rift Valley fever working group. Developing a research agenda and a comprehensive national prevention and response plan for Rift Valley fever in the United States. Emerg Infect Dis 2007;(August) [serial on the Internet]. Available from: http:\/\/www:cdc.gov\/EID\/content\/13\/8\/el.htm [cited 29.10.07].","DOI":"10.3201\/eid1308.070551"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0055","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/oxfordjournals.aje.a113471","article-title":"A Rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up","volume":"116","author":"Kark","year":"1982","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/inf.1982.14.issue-2.06","article-title":"Rift Valley fever virus vaccine trial: study of side-effects in humans","volume":"14","author":"Niklasson","year":"1982","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0264-410X(85)90061-1","article-title":"Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans","volume":"3","author":"Niklasson","year":"1985","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0070","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4049\/jimmunol.89.5.660","article-title":"The development of a formalin-killed Rift Valley fever virus vaccine for use in man","volume":"89","author":"Randall","year":"1962","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0075","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4269\/ajtmh.1963.12.611","article-title":"Rift Valley fever vaccine","volume":"12","author":"Randall","year":"1963","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0080","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4049\/jimmunol.93.2.293","article-title":"Immunization against Rift Valley Fever virus, studies on the immunogenicity of lyophilized formalin-inactivated vaccine","volume":"93","author":"Randall","year":"1964","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0264-410X(85)90060-X","article-title":"A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison or intradermal versus subcutaneous injection","volume":"3","author":"Kark","year":"1985","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0090","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0264-410X(86)90007-1","article-title":"Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trial","volume":"4","author":"Meadors","year":"1986","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0264-410X(99)00218-2","article-title":"Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience","volume":"18","author":"Pittman","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0100","doi-asserted-by":"crossref","first-page":"D69","DOI":"10.1016\/j.vaccine.2009.07.046","article-title":"Rift Valley fever vaccines","volume":"27","author":"Ikegami","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0105","first-page":"124","article-title":"Rift Valley fever vaccine for humans","volume":"vol. 3","author":"Eddy","year":"1981"},{"issue":"4","key":"10.1016\/j.vaccine.2011.02.037_bib0110","first-page":"197","article-title":"Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters","volume":"92","author":"Niklasson","year":"1984","journal-title":"Acts Pathol Microbiol Immunol Scand [C]"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0115","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2460\/ajvr.1980.41.10.1559","article-title":"Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep","volume":"41","author":"Harrington","year":"1980","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01311021","article-title":"Experimental Rift Valley fever in rhesus macaques","volume":"99","author":"Peters","year":"1988","journal-title":"Arch Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2011.02.037_bib0125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0882-4010(87)90126-4","article-title":"Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats","volume":"2","author":"Anderson","year":"1987","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0130","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1016\/j.vaccine.2005.08.034","article-title":"Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis, Hantaan virus, and Crimean Congo hemorrhagic fever virus","volume":"24","author":"Spik","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0135","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.vaccine.2010.01.001","article-title":"Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus","volume":"28","author":"Kortekaas","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0140","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","article-title":"Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever","volume":"24","author":"Wallace","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0145","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1016\/j.vaccine.2009.12.080","article-title":"Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity","volume":"28","author":"Reisler","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0150","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomized controlled trial","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0155","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4269\/ajtmh.2008.78.426","article-title":"Safety and Immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus na\u00efve children","volume":"78","author":"Simasathien","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0160","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4269\/ajtmh.1982.31.149","article-title":"Studies on the antigenic relationship among phleboviruses","volume":"31","author":"Tesh","year":"1982","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0165","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/JCM.24.4.612-614.1986","article-title":"Serological tests for detecting Rift Valley fever viral antibodies in sheep from the Nile Delta","volume":"24","author":"Scott","year":"1986","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0170","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1099\/vir.0.82860-0","article-title":"Phylogenetic relationships among sandfly fever group viruses (Phlebovirus: Bunyaviridae) based on the small genome segment","volume":"88","author":"Xu","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0175","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.4269\/ajtmh.2007.76.1194","article-title":"Antigenic and genetic relationships among Rift Valley fever virus and other selected members of the genus Phlebovirus (Bunyaviridae)","volume":"76","author":"Xu","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0180","doi-asserted-by":"crossref","unstructured":"LaBeaud AD, Muchiri EM, Ndzovu M, Mwanje MT, Muiruri S, Peters CJ, et al. Interepidemic Rift Valley fever virus seropositivity, Northeastern Kenya. Emerg Infect Dis 2008;(August) [serial on the Internet]. Available from: http:\/\/www.cdc.gov\/EID\/content\/14\/8\/1240.htm [cited 16.06.10].","DOI":"10.3201\/eid1408.080082"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0185","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2334-7-120","article-title":"Evaluation of immune response to hepatitis B vaccine in health care workers at a tertiary care hospital in Pakistan: an observational prospective study","volume":"7","author":"Zeeshan","year":"2007","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0190","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/BF00146405","article-title":"Immune response to anti-HBV vaccination: study of conditioning factors","volume":"4","author":"Corrao","year":"1988","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0195","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/ije\/23.5.1078","article-title":"Sex differences in the humoral antibody response to live measles vaccine in young adults","volume":"23","author":"Green","year":"1994","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0200","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1001\/archinternmed.2008.513","article-title":"Half- vs full-dose trivalent inactivated influenza vaccine (2004\u20132005): age, dose, and sex effects on immune responses","volume":"168","author":"Engler","year":"2008","journal-title":"Arch Int Med"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0205","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1016\/j.vaccine.2008.04.054","article-title":"Sexual dimorphism of humoral immunity with human vaccines","volume":"26","author":"Cook","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0210","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0264-410X(01)00387-5","article-title":"Anthrax vaccine: short-term safety experience in humans","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0215","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.300.13.1532","article-title":"Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months","volume":"300","author":"Marano","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0220","doi-asserted-by":"crossref","first-page":"874","DOI":"10.4269\/ajtmh.1999.61.874","article-title":"An accelerated schedule for tick-borne encephalitis vaccine: the American military experience in Bosnia","volume":"6","author":"Craig","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0225","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.vaccine.2006.07.026","article-title":"Study of the serological response after vaccination against tick-borne encephalitis in Sweden","volume":"25","author":"Vene","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0230","unstructured":"Final Report FY99-11 (HP-99-11). Immunization of persons at risk of exposure to eastern equine encephalitis virus: continued assessment of the safety and effectiveness of eastern equine encephalitis vaccine, inactivated, TSI-GSD 104, A phase 2 study. USAMRIID Human Use Committee; 2009."},{"key":"10.1016\/j.vaccine.2011.02.037_bib0235","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.virol.2008.12.012","article-title":"Vaccination with virus-like particles protects mice against lethal infection of Rift Valley fever virus","volume":"385","author":"Naslund","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0240","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1743-422X-6-6","article-title":"Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley fever virus cDNA constructs","volume":"6","author":"Lagerqvist","year":"2009","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0245","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1017\/S0950268808001696","article-title":"An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus","volume":"137","author":"Heise","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0250","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1128\/CVI.00182-09","article-title":"A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity","volume":"16","author":"Holman","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0255","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.virol.2009.11.001","article-title":"A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge","volume":"397","author":"Mandell","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0260","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.vaccine.2009.12.062","article-title":"Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge","volume":"28","author":"De Boer","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0265","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.vaccine.2010.02.018","article-title":"Protection against lethal Rift Valley fever (RVFV) infection in transgenic IFNAR(\u2212\/\u2212) mice induced by different DNA vaccination regimens","volume":"28","author":"Lorenzo","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0270","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1016\/j.vaccine.2010.04.048","article-title":"Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector","volume":"28","author":"Kortekaas","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0275","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1016\/j.vaccine.2010.04.085","article-title":"Evaluation of the efficacy and safety of the Rift Valley fever clone 13 vaccine in sheep","volume":"23","author":"Dungu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0280","first-page":"95","article-title":"Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep","volume":"69","author":"Hunter","year":"2002","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0285","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0034-5288(92)90029-2","article-title":"Comparison of the pathogenicity for pregnant sheep of Rift Valley fever virus and a live attenuated vaccine","volume":"52","author":"Baskerville","year":"1992","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0290","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2460\/ajvr.1987.48.07.1042","article-title":"Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes","volume":"48","author":"Morrill","year":"1987","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0295","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","article-title":"Safety and efficacy of a mutagen-attenuated Rift Valley fever vaccine in cattle","volume":"58","author":"Morill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0300","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2460\/ajvr.1997.58.10.1110","article-title":"Safety of a mutagen-attenuated Rift Valley fever vaccine in fetal and neonatal bovines","volume":"58","author":"Morill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0305","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0035-9203(80)90167-4","article-title":"Rift Valley fever as a possible cause of human abortions","volume":"74","author":"Abdel-Azia","year":"1980","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.02.037_bib0310","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1017\/S0950268800068011","article-title":"Rift Valley fever: a sero-epidemiological survey among pregnant women in Mozambique","volume":"99","author":"Niklasson","year":"1987","journal-title":"Epidemiol Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11002507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11002507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T02:02:07Z","timestamp":1740967327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11002507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":62,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0264410X11002507"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.02.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}